Harbour Capital Advisors’s Avanos Medical AVNS Stock Holding History

Harbour Capital Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-24	Closed	-$914	–	268
2017 Q1	$914	Buy	+24	New	+$935	﹤0.01%	670

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Harbour Capital Advisors's AVNS Position: Q2 2017 in Review

Harbour Capital Advisors sold out of Avanos Medical (AVNS) in Q2 2017, closing a stake of 24 shares — an estimated $914 sold.

Harbour Capital Advisors first reported a position in AVNS in Q1 2017 and held it in 1 quarter. The position peaked at $914 in Q1 2017. 328 funds tracked by Wall St. Rank hold AVNS as of Q2 2017.

Harbour Capital Advisors reported no remaining Avanos Medical position as of Q2 2017 after selling out during the quarter.
Harbour Capital Advisors sold 24 Avanos Medical shares in Q2 2017, an estimated $914.
Harbour Capital Advisors first reported a position in Avanos Medical in Q1 2017 and held it in 1 quarter.
Harbour Capital Advisors's Avanos Medical position peaked at $914 in Q1 2017.
328 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2017.

Based on Harbour Capital Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.